Medicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC)
The company is on track to complete the interim data analysis before the end of Q1 2025 and to submit the findings to the U.S ...
Medicus Pharma Ltd: Medicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC)
Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is also pleased to announce that its phase 2 clinical study (SKNJCT-003) which is currently ...
The EMBO Journal19h
LATS1/2 inactivation in the mammary epithelium drives the evolution of a tumor-associated niche
LATS1/2-inactivation and consequent nuclear YAP/TAZ hyperactivation in the mammary epithelium drives the development of a pro ...
emjreviews.com20h
Neoadjuvant T-VEC Shows Promise for Difficult-to-Treat Basal Cell Carcinoma
T-VEC enables BCC resectability in 50% of cases, showing promise as a neoadjuvant therapy with mild side effects.